Clinical application of quantitative glycomics

Wenjing Peng, Jingfu Zhao, Xue Dong, Alireza Banazadeh, Yifan Huang, Ahmed Hussien, Yehia Mechref

Research output: Contribution to journalReview articlepeer-review

31 Scopus citations


Introduction: Aberrant glycosylation has been associated with many diseases. Decades of research activities have reported many reliable glycan biomarkers of different diseases which enable effective disease diagnostics and prognostics. However, none of the glycan markers have been approved for clinical diagnosis. Thus, a review of these studies is needed to guide the successful clinical translation. Area covered: In this review, we describe and discuss advances in analytical methods enabling clinical glycan biomarker discovery, focusing only on studies of released glycans. This review also summarizes the different glycobiomarkers identified for cancers, Alzheimer’s disease, diabetes, hepatitis B and C, and other diseases. Expert commentary: Along with the development of techniques in quantitative glycomics, more glycans or glycan patterns have been reported as better potential biomarkers of different diseases and proved to have greater diagnostic/diagnostic sensitivity and specificity than existing markers. However, to successfully apply glycan markers in clinical diagnosis, more studies and verifications on large biological cohorts need to be performed. In addition, faster and more efficient glycomic strategies need to be developed to shorten the turnaround time. Thus, glycan biomarkers have an immense chance to be used in clinical prognosis and diagnosis of many diseases in the near future.

Original languageEnglish
Pages (from-to)1007-1031
Number of pages25
JournalExpert Review of Proteomics
Issue number12
StatePublished - Dec 2 2018


  • Biomarker
  • cancer and other diseases
  • clinical application
  • diagnosis
  • glycomics
  • prognosis


Dive into the research topics of 'Clinical application of quantitative glycomics'. Together they form a unique fingerprint.

Cite this